Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage

The preliminary predictions remain experimentally unvalidated, with further assessment needed to determine whether any program can advance.

Rhea-AI Summary

Nexentis Technologies (NXTS) announced that subsidiary MitoCareX Bio completed the initial computational screening stage of its drug-discovery initiative with Boltz. The initiative, launched in June 2026, uses Boltz’s AI models alongside MitoCareX’s discovery capabilities to identify potential small-molecule starting points for selected programs.

MitoCareX considers the preliminary predictions encouraging enough for further computational analysis and experimental validation. The findings have not been experimentally validated; further scientific assessment will determine whether they support advancing any program. MitoCareX retains control over its discovery programs and any candidates it advances through the initiative.

Positive

• Minor pointMitoCareX completed the initial computational screening stage of its drug-discovery initiative with Boltz.
• Minor pointMitoCareX retains control over its discovery programs and any candidates advanced through the initiative.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Preliminary predictions remain experimentally unvalidated; further scientific assessment will determine whether they support advancing any program.

Argus 15 min delay 8 alerts

+12.80% vs previous close $0.59 last price 84.8x rel. volume Open Argus

Details

Market move: NXTS +12.80% vs previous close. AI partnership milestone

+14.1% Peak in 1 min

$0.51 – $0.63 Day Range

$859,356 Mkt Cap at Last Price

On Oct 26, the day this news came out, the latest delayed price for NXTS is 12.80% above the previous close. Argus tracked a peak move of +14.1% during the session. Our momentum scanner has recorded 8 alerts for this stock so far that day. The latest delayed price is $0.59. Relative volume is exceptionally heavy at 84.8x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Previous AI Reports

1 past event · Latest: Jun 22

Same Type 1 event

1. Jun 22

   AI initiative launch

   24h Move

   +155.9%

   Launched the Boltz collaboration, combining MITOLINE structural modeling with Boltz models for SLC small-molecule discovery.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

computational screening, small-molecule, preclinical

3 terms

computational screening technical

"completed an initial computational screening stage under its drug-discovery initiative"

Computational screening is the use of computer models and algorithms to evaluate large sets of chemical compounds, biological targets, or candidate assets virtually, identifying those most likely to have desired properties before laboratory testing. Methods include molecular docking, similarity searches, physics-based simulations and machine‑learning models that score or rank candidates; the output is predictive, not conclusive, and serves to prioritize items for experimental validation because results depend on the quality of the models and input data and can produce false positives and false negatives.

small-molecule medical

"potential small-molecule starting points for selected discovery programs"

A small-molecule is a low-weight chemical compound designed to affect biological processes, often able to enter cells and be taken as a pill or simple injection. Investors watch small-molecule programs because they usually cost less and move faster through development than large biologics, have different manufacturing and patent dynamics, and face distinct competition and market-size implications—think of them as compact tools versus larger, more complex machines in a drugmaker’s toolbox.

preclinical medical

"advanced into preclinical or clinical development"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation

Ness Ziona, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has completed an initial computational screening stage under its drug-discovery initiative with Boltz, PBC (“Boltz”), an AI research lab focused on biomolecular foundation models and drug-discovery workflows. MitoCareX believes the preliminary computational predictions generated in this stage are encouraging and warrant further computational analysis and experimental validation.

Completion of this stage moves the initiative, announced in June 2026, from launch to an initial assessment of screening predictions. The predictions have not been experimentally validated and serve only as a starting point for evaluating potential follow-up research within MitoCareX’s small-molecule discovery programs.

“We believe that completing this first screening stage is an important step in translating our initiative with Boltz into research insights,” said David Palach, Chief Executive Officer of Nexentis. “We are focused on advancing proprietary discovery programs through disciplined, evidence-based decisions. These initial predictions give us a basis for planning next steps, and further validation will be essential to determining their significance.”

The initiative combines MitoCareX’s proprietary drug-discovery capabilities with Boltz’s AI models to identify potential small-molecule starting points for selected discovery programs. MitoCareX retains control over its discovery programs and any small-molecule candidates it advances through the initiative.

Further scientific assessment and validation will determine whether the preliminary predictions support advancing any program. No assurance can be given that any compound identified through the initiative will be advanced into preclinical or clinical development.

About MitoCareX Bio Ltd.

MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc., is advancing a focused drug-discovery platform designed to translate multidisciplinary scientific capabilities into potential therapeutic candidates. By integrating biology, chemistry and computationally enabled research, MitoCareX supports ongoing research activities directed toward candidate identification and development within its drug-discovery efforts. https://mitocarexbio.com/

About Nexentis Technologies Inc.

Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd., a drug-discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

For additional details, please visit https://nexentistech.com/

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “could,” “potential” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the significance of the preliminary computational predictions from the initial screening stage under MitoCareX’s drug-discovery initiative with Boltz; the potential for further computational analysis, experimental investigation and validation of such predictions; the assessment of next research steps and follow-up research opportunities within MitoCareX’s small-molecule discovery programs; the potential identification and advancement of small-molecule starting points or candidates; and the potential contribution of the initiative to MitoCareX’s broader discovery strategy. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, market and other conditions; our history of losses, our need for additional capital to fund our operations and our potential inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the risk that computational or AI-generated predictions may not be confirmed by experimental testing or may not identify viable candidates; our dependence on third-party collaborators, including Boltz, and their technologies; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates, including our renewable energy investments; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of the Nasdaq Capital Market; and the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026, and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What milestone did Nexentis subsidiary MitoCareX reach in its Boltz initiative?

MitoCareX completed the initial computational screening stage of its drug-discovery initiative with Boltz. The initiative, announced in June 2026, has moved from launch to an initial assessment of screening predictions.

Have MitoCareX’s AI drug-discovery predictions been experimentally validated?

The preliminary computational predictions have not been experimentally validated. MitoCareX considers them encouraging for further computational analysis and experimental investigation. Further scientific assessment and validation will determine whether they support advancing any program.